Wolves of Wall Street
Well not quite Wolves maybe but our visit to the world famous Wall Street and the New York Stock Exchange prompted howls of appreciation from all of those who saw our videos to support the Capital Markets Day organised by one of our favourite clients – Volition RX
See the video we prepared for the event by Clicking Here
Volition staged the event to update interested parties on its recent progress. Watch out for further announcements and videos from Volition, including the launch of a new venture into the world of veterinary health. Good Call Media also recorded videos at the event itself and these will be released shortly.
Good Call Media’s co-owner, Fiona Molloy, filming on Wall Street
“It has been a busy quarter with the public announcement of a number of initiatives and we were delighted to have the opportunity to discuss our plans at the 
Capital Markets Day event today,” commented Chief Executive Officer, Cameron Reynolds. “We would like to thank all those who attended, especially our speakers Professor Axel Imhof of Ludwig-Maximilians University of Munich and Associate Professor Heather Wilson-Robles of Texas A&M University.”
Following recently announced preliminary results from two proof of concept studies in lung cancer, Volition has signed a Memorandum of Understanding with the prestigious National Taiwan University through its wholly-owned subsidiary, Belgian Volition SPRL (“Belgian Volition”), to conduct a large-scale lung cancer study. Principal Investigator Professor
Chen Jin-Shing commented: “The early data of the Nu.QTMtechnology platform is promising but clearly larger scale studies are required. Lung cancer remains the deadliest of all the cancers and there is a high unmet clinical need for either a non-invasive early stage lung cancer detection test or for a triage test which can improve the specificity of the Low-Dose CT scan currently used.” Volition expects to release preliminary data relating to the first 600 patient samples in first quarter of 2020.
Volition has also executed a nonbinding Memorandum of Understanding with Shanghai Fosun Long March Medical Science Co., Ltd. with an expectation of negotiating and entering into a binding agreement to help facilitate the entrance of the Nu.QTMplatform into China. Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, commented: “We are happy to be able to announce this Memorandum of Understanding with Fosun Long March because, in addition to our plans to undertake clinical studies in colorectal cancer, lung cancer and ovarian cancer, we are also planning to jointly explore the development of Nu.QTMassays utilizing Fosun’s LUMIART-II Automated Chemiluminescence Immunoassay System, which could provide us with an additional platform for the Chinese market.”
